Johnson & Johnson seeks to charge 340B-enrolled disproportionate share hospitals full price for Xarelto and Stelara and issue ...

Johnson & Johnson is escalating its fight with the federal government over its controversial plan to change how it doles out ...

The New Jersey-based drugmaker is trying to get the courts’ backing to pay hospitals rebates for two drugs in the 340B drug ...

BioNTech said that it is acquiring the Chinese drugmaker Biotheus for $800 million to bolster its cancer strategy. The two ...

We are focused on cash conversion and reducing net financial debt. (Wolfgang Nickl, CFO) Q: What is the expected impact of ...

The pharma is trying to win court backing to pay hospitals rebates for two drugs in the 340B drug discount program, instead ...

Partially offsetting this are declines in cardiovascular drug Xarelto due to loss of exclusivity events across various territories, which is putting pressure on both revenue growth and profit margins.

Johnson & Johnson sued the U.S. Health and Human Services Department on Tuesday, accusing the agency of blocking its plan to ...

The lawsuit escalates the pharmaceutical industry’s fight to rein in the federal drug-discount program known as 340B ... The ...

Johnson & Johnson files suit against HHS over 340B program, proposing hospitals pay full price upfront for drugs and receive ...

Despite generic headwinds to Xarelto and challenges across different sectors of the conglomerate suggesting “twists and turns ...

A new study found that many people on Medicare with low to moderate incomes don't have enough money to pay for a hospital ...